ArticleBiosensors2026
Portable Point-of-Care Uric Acid Detection System with Cloud-Based Data Analysis and Patient Monitoring.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Uric acid is closely related to diseases such as gout, kidney failure, and metabolic disorders. A conventional method for measuring uric acid over 24 h is time intensive and cumbersome for patients who have to take samples to the hospital. At present, hospitals use only laboratory instruments to determine 24-h uric acid concentrations in the urine. This study presents the proof-of-concept of a portable point-of-care tool called Uricia, designed to improve the quality of life of patients monitoring uric acid. Spectrophotometry was performed at a fixed wavelength of 295 nm. The urine sample contained within the cuvette absorbs ultraviolet light, with uric acid specifically responsible for this absorption, thereby allowing the device to measure its concentration. An internal calibration algorithm was used to accommodate the nonlinear optical response of Uricia and was calibrated to a benchtop GENESYS 10S UV-Vis spectrophotometer. The experiments further evaluated potential urinary interferences, revealing that while most constituents had minimal impact, ascorbic acid demonstrated the highest interference, contributing up to 15% of the total signal at high physiological concentrations. This device and the corresponding spectrophotometry method revealed that high concentrations of uric acid precipitated insoluble crystals. A dilution set to an alkali solution vial to be premixed and dissolve the uric acid crystals was added, increasing the detection window to 10 mg/dL, with an LOD of 0.0232 mg/dL and LOQ of 0.0702 mg/dL. Cloud-based data measurement enables spot analysis, which is meant to provide insight into patient status development. These results validated the technical architecture of a controlled matrix for measuring uric acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.